Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Dugo, Matteo"'
Autor:
Minna E; Department of Experimental Oncology and Molecular Medicine, Molecular Mechanisms Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Romeo P; Department of Experimental Oncology and Molecular Medicine, Molecular Mechanisms Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Dugo M; Department of Experimental Oncology and Molecular Medicine, Functional Genomics Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Cecco L; Department of Experimental Oncology and Molecular Medicine, Functional Genomics Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Todoerti K; Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy., Pilotti S; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Perrone F; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Seregni E; Department of Diagnostic Imaging and Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Agnelli L; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Neri A; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy., Greco A; Department of Experimental Oncology and Molecular Medicine, Molecular Mechanisms Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Borrello MG; Department of Experimental Oncology and Molecular Medicine, Molecular Mechanisms Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Oncotarget [Oncotarget] 2016 Mar 15; Vol. 7 (11), pp. 12731-47.
Autor:
Callari M; Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo, 42, 20133 Milan, Italy., Musella V; Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo, 42, 20133 Milan, Italy., Di Buduo E; Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo, 42, 20133 Milan, Italy., Sensi M; Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo, 42, 20133 Milan, Italy., Miodini P; Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo, 42, 20133 Milan, Italy., Dugo M; Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo, 42, 20133 Milan, Italy., Orlandi R; Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo, 42, 20133 Milan, Italy., Agresti R; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133 Milan, Italy., Paolini B; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133 Milan, Italy., Carcangiu ML; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133 Milan, Italy., Cappelletti V; Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo, 42, 20133 Milan, Italy. Electronic address: vera.cappelletti@istitutotumori.mi.it., Daidone MG; Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo, 42, 20133 Milan, Italy. Electronic address: mariagrazia.daidone@istitutotumori.mi.it.
Publikováno v:
Molecular oncology [Mol Oncol] 2014 Oct; Vol. 8 (7), pp. 1278-89. Date of Electronic Publication: 2014 May 04.
Autor:
Galvan A; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Frullanti E, Anderlini M, Manenti G, Noci S, Dugo M, Ambrogi F, De Cecco L, Spinelli R, Piazza R, Pirola A, Gambacorti-Passerini C, Incarbone M, Alloisio M, Tosi D, Nosotti M, Santambrogio L, Pastorino U, Dragani TA
Publikováno v:
Carcinogenesis [Carcinogenesis] 2013 Dec; Vol. 34 (12), pp. 2767-73. Date of Electronic Publication: 2013 Aug 25.
Autor:
Callari M; Functional Genomics Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Dugo M, Musella V, Marchesi E, Chiorino G, Grand MM, Pierotti MA, Daidone MG, Canevari S, De Cecco L
Publikováno v:
PloS one [PLoS One] 2012; Vol. 7 (9), pp. e45105. Date of Electronic Publication: 2012 Sep 13.
Autor:
Rinchai, Darawan, Verzoni, Elena, Huber, Veronica, Cova, Agata, Squarcina, Paola, De Cecco, Loris, Braud, Filippo, Ratta, Raffaele, Dugo, Matteo, Lalli, Luca, Vallacchi, Viviana, Rodolfo, Monica, Roelands, Jessica, Castelli, Chiara, Chaussabel, Damien, Procopio, Giuseppe, Bedognetti, Davide, Rivoltini, Licia
Publikováno v:
Clinical and Translational Medicine
Clinical and Translational Medicine, Vol 11, Iss 6, Pp n/a-n/a (2021)
Clinical and Translational Medicine, Vol 11, Iss 6, Pp n/a-n/a (2021)
Background The combination of immune checkpoint blockade (ICB) with standard therapies is becoming a common approach for overcoming resistance to cancer immunotherapy in most human malignancies including metastatic renal cell carcinoma (mRCC). In thi
Autor:
Rossella Canese, Elda Tagliabue, Patrizia Nanni, Egidio Iorio, Daniele Morelli, Massimo Di Nicola, Simona Faraci, Patrizia Casalini, Lorenzo Castagnoli, Matteo Dugo, Claudio Vernieri, Ada Koschorke, Serenella M. Pupa
Publikováno v:
Journal of Cellular Physiology
Despite different molecular tumor profiles indicate that human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) levels mirror HER2 addiction and trastuzumab benefit in HER2-positive breast cancer (BC), the identification of noninvasive
Autor:
Laura Botti, Valeria Cancila, Tiziana Ada Renzi, Mario P. Colombo, Maurizio Marrale, Sabina Sangaletti, Claudio Tripodo, Lucia Bongiovanni, Milena Perrone, Matteo Milani, Andrea Massimiliano Tomirotti, Claudia Chiodoni, Matteo Dugo
Publikováno v:
Cancer research. 80(3)
The presence of a growing tumor establishes a chronic state of inflammation that acts locally and systemically. Bone marrow responds to stress signals by expanding myeloid cells endowed with immunosuppressive functions, further fostering tumor growth
Autor:
Lorena Citterio, Matteo Dugo, Chiara E. Cotroneo, Tommaso A. Dragani, Paolo Manunta, Matteo Incarbone, Francesca Colombo, Luigi Santambrogio, Simona Delli Carpini, Giulia Pintarelli, Antonella Galvan, Davide Tosi, Sara Noci
Publikováno v:
Scientific reports (Nature Publishing Group) 7 (2017). doi:10.1038/srep42185
info:cnr-pdr/source/autori:Pintarelli, Giulia; Cotroneo, Chiara Elisabetta; Noci, Sara; Dugo, Matteo; Galvan, Antonella; Delli Carpini, Simona; Citterio, Lorena; Manunta, Paolo; Incarbone, Matteo; Tosi, Davide; Santambrogio, Luigi; Dragani, Tommaso A.; Colombo, Francesca/titolo:Genetic susceptibility variants for lung cancer: Replication study and assessment as expression quantitative trait loci/doi:10.1038%2Fsrep42185/rivista:Scientific reports (Nature Publishing Group)/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume:7
Scientific Reports
info:cnr-pdr/source/autori:Pintarelli, Giulia; Cotroneo, Chiara Elisabetta; Noci, Sara; Dugo, Matteo; Galvan, Antonella; Delli Carpini, Simona; Citterio, Lorena; Manunta, Paolo; Incarbone, Matteo; Tosi, Davide; Santambrogio, Luigi; Dragani, Tommaso A.; Colombo, Francesca/titolo:Genetic susceptibility variants for lung cancer: Replication study and assessment as expression quantitative trait loci/doi:10.1038%2Fsrep42185/rivista:Scientific reports (Nature Publishing Group)/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume:7
Scientific Reports
Many single nucleotide polymorphisms (SNPs) have been associated with lung cancer but lack confirmation and functional characterization. We retested the association of 56 candidate SNPs with lung adenocarcinoma risk and overall survival in a cohort o